In a laboratory at the University of Basel, something extraordinary is growing inside a structure just eight millimeters thick. It's not a real organ. It's not even natural tissue. Yet it produces blood, just as bone marrow does in your body right now.
We are witnessing an absolute first in bioengineering: the creation of a bone marrow model built entirely from human cells, published in the journal Cell Stem Cell. This isn't just a technical achievement. It's a breakthrough that could redefine how we study blood diseases and test new therapies for leukemia.
Where We Were: The Limits of Traditional Research
Until now, understanding how bone marrow works meant making a difficult choice. On the one hand, animal models: Laboratory mice have taught us a great deal, but they remain, precisely, mice. Their hematopoietic biology differs from ours in ways that matter, especially when it comes to testing drugs that will later work in humans.
On the other hand, cell cultures in the laboratory: simple, controllable, but terribly simplified. As Professor Ivan Martin explains, co-author of the study, these cultures fail to reproduce the architectural complexity of real marrow, that intricate network of bone cells, blood vessels, nerves, and immune cells working together.
Bone marrow is not a uniform tissue. It is a mosaic of specialized microenvironments, called "niches." One of these, the endosteal niche, is particularly important because it is located close to the bone surface and is crucial for both blood formation and treatment resistance in blood cancers. Until now, No human model included all of these cellular components.
Bone marrow, where we are: building a biological factory
The construction of this bone marrow model starts from an artificial scaffold made of hydroxyapatite, the same mineral that makes bones and teeth strong. But the real innovation lies in what Swiss researchers have grown on top of it.
They used human cells reprogrammed into pluripotent stem cells, those extraordinarily versatile cells that can transform into any cell type depending on the chemical signals they receive. By integrating these cells into the artificial bone structure, the team was able to guide them through specific differentiation processes to produce the full range of cell types present in natural marrow.
The result is a three-dimensional system eight millimeters in diameter and four millimeters thick, larger than previous systems. But size matters less than function: this model keeps human blood formation active in the laboratory for weeks, recreating what is essentially a miniaturized but functioning version of our “blood factory.”
Bone marrow, the road to concrete applications
The ability to replicate complexity The use of human bone marrow opens up possibilities that until recently seemed impossible. The first concerns blood cancer research. Leukemia, the most common blood cancer in children and adolescents, directly affects the bone marrow. Approximately 3.500-4.000 new cases are diagnosed each year in the United States alone.
Testing new drugs against these diseases would ideally require a system that faithfully reproduces how tumor cells interact with the bone marrow environment. Now we have it. Recent studies have already demonstrated how similar bioengineered models can evaluate the efficacy of CAR-T therapies for acute myeloid leukemia, finding side effects that traditional methods had not anticipated.
But there's an even more fascinating aspect: personalized medicine. In the future, this model could be generated from individual patient cells. Imagine being able to test which drug works best on a replica of your bone marrow, before even starting treatment. No more trial-and-error therapies, but interventions tailored to your specific biology.
The obstacles to overcome
As Dr. points out Andrés García García, co-author of the study, to use this system in large-scale drug testing, it will be necessary to reduce its size. Eight millimeters is perfect for studying biological processes, but to simultaneously test dozens of different compounds and dosages, something even more compact and standardizable is needed.
Then there's the issue of scalability. Producing these models requires time, specific skills, and resources. Before they become a routine tool in laboratories around the world, it will be necessary to optimize protocols, automate processes, and make the technology accessible even to research centers with limited budgets.
And finally, there's the ongoing debate about alternative models to animals. Yes, this approach promises to reduce reliance on animal testing. But will it completely replace it? It's too early to say for now. In vitro models, however sophisticated, cannot yet replicate the systemic complexity of an entire organism with all its biological feedback loops.
What we bring with us
What was built in Basel is not just a bone marrow model. It demonstrates that we can recreate complex biological systems in the laboratory using reprogrammed human cells. It proves that bioengineering can bridge the gap between the artificial simplicity of cell cultures and the irreducible complexity of the human body.
In ten years, Perhaps we'll go to the doctor and have a few cells removed. In the lab, those cells will become a biological avatar of our bone marrow, on which to test tailored therapies. In twenty yearsPerhaps this technology will help transform leukemia from a devastating disease to a manageable condition, thanks to drugs designed by testing thousands of molecules in bioengineered bone marrow models.
So far, however, we have achieved a goal that seemed impossible: we have taught reprogrammed human cells to organize themselves into a functioning blood factory, in a structure that fits in the palm of a hand. And this, alone, is already extraordinary.
